The domestic AI healthcare leader, YIDU TECH (02158), announced its annual results for the period ending March 31, 2026, on June 30. The financial report is full of highlights, marking the company's first annual profit. The company recorded an annual profit of RMB 78.766 million for the reporting period, exceeding its previously announced profit alert forecast of RMB 55 million to RMB 70 million. Net profit attributable to owners of the parent was RMB 72.709 million, also significantly surpassing the forecasted range of RMB 41 million to RMB 56 million, with the upper limit exceeded by 30%.

Revenue increased by approximately 14.6% year-on-year to RMB 820 million. Notably, the net cash flow from operating activities turned positive in the second half of the reporting period, recording RMB 29.3 million. Meanwhile, the overall gross profit margin further improved to 36.4% compared to the same period last year, indicating an upward trend in profitability.

The performance announcement shows that the company's three main business segments all maintained steady growth, working together to form a solid performance foundation. AI for Medical (big data platform and solutions), as the core foundational business, generated revenue exceeding RMB 380 million this fiscal year, a year-on-year increase of 10.2%.

This business has served 133 leading domestic hospitals and 54 regulatory agencies, with its hospital network covering over 12,000 institutions. During the reporting period, it successively won bids for major provincial projects such as the Hainan Infectious Disease Surveillance Platform and the Smart Health Island, while also deepening cooperation with renowned top-tier hospitals like Beijing Cancer Hospital and Peking University First Hospital. Improved operational efficiency in this segment led to a significant increase in gross margin, rising from 29.7% last fiscal year to 39.7% in the reporting period.

The AI for Life Sciences (life science solutions) segment generated revenue exceeding RMB 270 million, a year-on-year increase of 9.4%. The business continues to deepen its services across the entire pharmaceutical lifecycle, having participated in or completed over 516 clinical research projects, including both sponsor-initiated and investigator-initiated trials, and over 320 prospective and retrospective real-world studies. Seventeen of the top 20 multinational pharmaceutical companies are clients of YIDU TECH.

The AI for Care (health management platform and solutions) segment generated revenue of approximately RMB 170 million, a significant year-on-year surge of 37.6%, making it the fastest-growing among the three segments. The company has served as the main operating platform for Shenzhen's Huiminbao for four consecutive years and for Beijing's Inclusive Health Insurance for five consecutive years, with both projects having large-scale enrollment. Its intelligent fast-claims model has significantly improved claims processing efficiency.

Furthermore, its digital diabetes therapy has been implemented in 105 core medical institutions across five cities and counties including Sanya, Qionghai, Wanning, and Lingshui, and has extended to more regions such as Shanxi Province and Tianjin. The three business tracks are advancing together, laying a solid foundation for the long-term development of YIDU TECH.